Oncology biotech Immuneering files for a $100 million IPO

Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Immuneering’s oncology programs target mutations of the MAPK and mTOR pathways, whicRead More